This user-friendly solution empowers clinicians to make informed decisions while fostering improved communication with patients. Committed to driving innovation, PD Neurotechnology aims to elevate the standards of patient care. Their Greek branch is located in Athens, complemented by research, development, and production facilities in Ioannina, allowing them to operate on a global scale.

To date, over 1,000 Parkinson’s patients have utilized the PDMonitor to manage their symptoms, with the technology being adopted in both private and hospital practices across the UK, France, Austria, Germany, Italy, Spain, Sweden, Ireland, Greece, and Cyprus. Clinical trials conducted in Germany, Italy, and Greece have demonstrated high reliability and specificity levels, with symptom detection accuracy reaching up to 93 percent.

PD Neurotechnology secured a strategic €2.7 investment of working capital from Crimson Internation Investment, Onassis Foundation, Big Pi Venture, the National Bank of Greece, and PDNTECH Investors S.R.L. to support their international growth plans. 

PD Neurotechnology in Three:

What problem is the company solving? PD Neurotechnology is solving the problem of inadequate continuous monitoring of Parkinson's disease symptoms, which traditional methods often fail to address.

What’s innovative about the company? The company is innovative due to its non-invasive PDMonitor, a wearable device that continuously tracks and analyzes Parkinson’s symptoms while enhancing patient-provider communication through a mobile app.

Who can use the company? Parkinson’s patients and healthcare providers in both private and hospital settings can use PD Neurotechnology's solutions.